Crk-L Inhibitors
Crk-L inhibitors constitute a class of compounds designed to modulate cellular responses by selectively targeting Src family kinases, intricate players in signaling pathways associated with Crk-L. Among these inhibitors, Dasatinib, a dual BCR-ABL and Src family kinase inhibitor, disrupts Src-dependent signaling cascades, indirectly inhibiting Crk-L through interference with upstream events crucial for Crk-L activation. Similarly, Bosutinib and Saracatinib exert their effects by modulating Src kinases, thereby altering cellular responses and influencing Crk-L pathways. Dasatinib, as a potent inhibitor of BCR-ABL and Src family kinases, disrupts the intricate signaling networks associated with Crk-L. By selectively targeting Src kinases, Dasatinib indirectly modulates Crk-L activation, influencing downstream cellular processes governed by Crk-L. Bosutinib and Saracatinib similarly contribute to this modulation by affecting Src kinases, providing additional layers to the strategic inhibition of Crk-L.
The PP2 family of inhibitors, including A-419259, SU6656, WH-4-023, and PP1, along with other compounds like AZM475271, CGP77675, AZD0424, and KX2-391, collectively highlight the diverse strategies employed to modulate Crk-L activity. These inhibitors, by selectively targeting Src family kinases, disrupt the finely tuned orchestration of cellular responses governed by Crk-L. The interconnected signaling pathways influenced by these inhibitors showcase the intricate regulatory networks associated with Crk-L. In summary, this class of Crk-L inhibitors illustrates a strategic approach to modulating Crk-L activity by targeting key nodes within the interconnected signaling pathways. By focusing on Src family kinases, these inhibitors provide valuable tools for understanding and potentially controlling Crk-L-associated cellular processes. The diverse mechanisms of action within this class underscore the intricate nature of Crk-L regulation, offering researchers a comprehensive toolkit for investigating the role of Crk-L in various physiological and pathological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a dual BCR-ABL and Src family kinase inhibitor. By blocking Src kinases, it interferes with the Src-dependent signaling cascades that intersect with pathways involving Crk-L, modulating cellular responses and indirectly inhibiting Crk-L through disruption of upstream signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Its inhibition of Src kinases disrupts the signaling cascades connected to Crk-L, indirectly influencing Crk-L by altering cellular responses and modulating upstream events crucial for Crk-L activation. | ||||||
A 419259 trihydrochloride | 1435934-25-0 | sc-361094 | 5 mg | $213.00 | 6 | |
A-419259 is a selective inhibitor of Src family kinases. By blocking Src kinases, it interferes with the signaling cascades that intersect with pathways involving Crk-L, modulating cellular responses and indirectly inhibiting Crk-L through disruption of upstream signaling. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 is a selective inhibitor of Src family kinases. Its impact on Src kinases disrupts signaling cascades that converge with Crk-L pathways, indirectly influencing Crk-L by altering cellular responses and modulating upstream events crucial for Crk-L activation. | ||||||
WH-4-023 | 837422-57-8 | sc-507457 | 10 mg | $172.00 | ||
WH-4-023 is a selective inhibitor of Src family kinases. By blocking Src kinases, it interferes with the signaling cascades that intersect with pathways involving Crk-L, modulating cellular responses and indirectly inhibiting Crk-L through disruption of upstream signaling. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $86.00 $145.00 | 6 | |
PP1 is a selective inhibitor of Src family kinases. Its inhibition of Src kinases disrupts the signaling cascades connected to Crk-L, indirectly influencing Crk-L by altering cellular responses and modulating upstream events crucial for Crk-L activation. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib is a dual BCR-ABL and Src family kinase inhibitor. Its impact on Src kinases disrupts signaling cascades that converge with Crk-L pathways, indirectly influencing Crk-L by altering cellular responses and modulating upstream events crucial for Crk-L activation. | ||||||
KX2-391 | 897016-82-9 | sc-364520 sc-364520A | 5 mg 50 mg | $180.00 $1140.00 | ||
KX2-391 is a selective inhibitor of Src family kinases. Its inhibition of Src kinases disrupts the signaling cascades connected to Crk-L, indirectly influencing Crk-L by altering cellular responses and modulating upstream events crucial for Crk-L activation. | ||||||